230 related articles for article (PubMed ID: 19047127)
1. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
Clamp AR; Schöffski P; Valle JW; Wilson RH; Marreaud S; Govaerts AS; Debois M; Lacombe D; Twelves C; Chick J; Jayson GC;
Cancer Chemother Pharmacol; 2008 Apr; 61(4):579-85. PubMed ID: 17520255
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
5. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ
Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263
[TBL] [Abstract][Full Text] [Related]
6. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
8. [Phase I study of raltitrexed (ZD-1694)].
Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
[TBL] [Abstract][Full Text] [Related]
9. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Chu QS; Cianfrocca ME; Goldstein LJ; Gale M; Murray N; Loftiss J; Arya N; Koch KM; Pandite L; Fleming RA; Paul E; Rowinsky EK
Clin Cancer Res; 2008 Jul; 14(14):4484-90. PubMed ID: 18628463
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
Ciuleanu T; Diculescu M; Hoepffner NM; Trojan J; Sailer V; Zalupski M; Herrmann T; Roth A; Chick J; Brock K; Albert D; Philip PA
Invest New Drugs; 2007 Aug; 25(4):385-90. PubMed ID: 17364234
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
16. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
[TBL] [Abstract][Full Text] [Related]
19. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
[TBL] [Abstract][Full Text] [Related]
20. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Falk S; Anthoney A; Eatock M; Van Cutsem E; Chick J; Glen H; Valle JW; Drolet DW; Albert D; Ferry D; Ajani J
Br J Cancer; 2006 Aug; 95(4):450-6. PubMed ID: 16880795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
